NCT00449501

Brief Summary

The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
134

participants targeted

Target at P25-P50 for phase_3 asthma

Timeline
Completed

Started Mar 2007

Shorter than P25 for phase_3 asthma

Geographic Reach
1 country

46 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

March 16, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 20, 2007

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
Last Updated

January 24, 2011

Status Verified

January 1, 2011

First QC Date

March 16, 2007

Last Update Submit

January 21, 2011

Conditions

Keywords

Mild AsthmaModerate Asthma

Outcome Measures

Primary Outcomes (1)

  • To determine whether subjects respond similarly to the Onset of Effect Questionnaire items 2 and 5 when administered post-dose versus pre-dose and does that difference favour a bronchodilator treatment group over a non-bronchodilator treatment group

Secondary Outcomes (1)

  • To determine if there is an association between the immediate physiological response to medication and the responses to OEQ items 2 and 5 and to determine what subjects mean when they say they feel their asthma maintenance medication 'working right away

Interventions

Also known as: Symbicort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female, \> 18 years of age
  • Mild to moderate asthma requiring treatment with an inhaled corticosteroid
  • Diagnosis of asthma for at least 6 months

You may not qualify if:

  • Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
  • Subjects with severe asthma, as judged by investigator
  • Any significant disease or disorder that may jeopardize a subject's safety

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (46)

Research Site

Muscle Shoals, Alabama, United States

Location

Research Site

Little Rock, Arkansas, United States

Location

Research Site

Anaheim, California, United States

Location

Research Site

Los Angeles, California, United States

Location

Research Site

Palmdale, California, United States

Location

Research Site

Rolling Hills Estates, California, United States

Location

Research Site

Denver, Colorado, United States

Location

Research Site

Wheat Ridge, Colorado, United States

Location

Research Site

Stamford, Connecticut, United States

Location

Research Site

Wilmington, Delaware, United States

Location

Research Site

Miami, Florida, United States

Location

Research Site

Avon, Indiana, United States

Location

Research Site

Iowa City, Iowa, United States

Location

Research Site

Shawnee Mission, Kansas, United States

Location

Research Site

Mandeville, Louisiana, United States

Location

Research Site

Wheaton, Maryland, United States

Location

Research Site

Bay City, Michigan, United States

Location

Research Site

Chesterfield, Missouri, United States

Location

Research Site

Kansas City, Missouri, United States

Location

Research Site

McCook, Nebraska, United States

Location

Research Site

Scottsbluff, Nebraska, United States

Location

Research Site

Brick, New Jersey, United States

Location

Research Site

Princeton, New Jersey, United States

Location

Research Site

North Syracuse, New York, United States

Location

Research Site

Bismarck, North Dakota, United States

Location

Research Site

Fargo, North Dakota, United States

Location

Research Site

Akron, Ohio, United States

Location

Research Site

Oklahoma City, Oklahoma, United States

Location

Research Site

Bend, Oregon, United States

Location

Research Site

Lake Oswego, Oregon, United States

Location

Research Site

Bensalem, Pennsylvania, United States

Location

Research Site

Feasterville, Pennsylvania, United States

Location

Research Site

Pittsburgh, Pennsylvania, United States

Location

Research Site

East Providence, Rhode Island, United States

Location

Research Site

Charleston, South Carolina, United States

Location

Research Site

Gaffney, South Carolina, United States

Location

Research Site

Greer, South Carolina, United States

Location

Research Site

Rapid City, South Dakota, United States

Location

Research Site

Watertown, South Dakota, United States

Location

Research Site

Boerne, Texas, United States

Location

Research Site

Dallas, Texas, United States

Location

Research Site

El Paso, Texas, United States

Location

Research Site

San Antonio, Texas, United States

Location

Research Site

Waco, Texas, United States

Location

Research Site

Provo, Utah, United States

Location

Research Site

Spokane, Washington, United States

Location

Related Publications (1)

  • Leidy NK, Gutierrez B, Lampl K, Uryniak T, O'Brien CD. Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma. 2009 Dec;46(10):1006-12. doi: 10.3109/02770900903301260.

Related Links

MeSH Terms

Conditions

Asthma

Interventions

BudesonideBudesonide, Formoterol Fumarate Drug Combination

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsFormoterol FumarateEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesDrug CombinationsPharmaceutical Preparations

Study Officials

  • Tomas LG Andersson, MD

    AstraZenenca

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 16, 2007

First Posted

March 20, 2007

Study Start

March 1, 2007

Study Completion

November 1, 2007

Last Updated

January 24, 2011

Record last verified: 2011-01

Locations